Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 14/20 | 0.45 |
| ▸ | PTGFR | P43088 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL168304 | 0.81 | CTSA (0.47) | CTSALMNAMAPTNISCH | |
| SCHEMBL21656326 | 0.79 | ADRB2 (0.40) | CTSANISCHADRB2ADRB1 | |
| SCHEMBL257263 | 0.78 | LMNA (0.55) | CTSALMNAMAPTNISCH | |
| Hydrochloric Acid SCHEMBL11798359 | 0.76 | NISCH (0.42) | CTSALMNAMAPTNISCHADRB2 | |
| Hydrochloric Acid SCHEMBL11651005 | 0.75 | NISCH (0.45) | CTSALMNAMAPTNISCHADRB2 | |
| SCHEMBL21632020 | 0.74 | SGMS2 (0.40) | CTSAPTGFRMAPTADRB2ADRB1 | |
| SCHEMBL11624515 | 0.73 | NISCH (0.53) | LMNANISCHADRB2ADRB1 | |
| SCHEMBL349398 | 0.72 | GABBR2 (0.61) | CTSALMNANISCH | |
| SCHEMBL8278779 | 0.72 | NISCH (0.45) | LMNAMAPTNISCHADRB2ADRB1 | |
| Potassium Ion SCHEMBL28641891 | 0.72 | ADRB2 (0.40) | CTSAADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136296-B2 | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-05 | — | — | US | disclosed |
| EP-3609869-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | Bayer Aktiengesellschaft (DE) | 2020-02-19 | — | — | EP | disclosed |
| US-20200031775-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031775-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | AADAC, NAT1, EPX | CTSA 36/4885PTGFR 1050/4885LMNA 694/4885 |
| US-11136296-B2 | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof | AADAC, NAT1, EPX | CTSA 36/4885PTGFR 1050/4885LMNA 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.